Diltiazem - Blue Note Pharmaceuticals

Drug Profile

Diltiazem - Blue Note Pharmaceuticals

Alternative Names: BNP 32,762; DOV Diltiazem

Latest Information Update: 07 Sep 2010

Price : $50

At a glance

  • Originator DOV Pharmaceutical
  • Developer Blue Note Pharmaceuticals
  • Class Antihypertensives; Benzazepines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Angina pectoris; Hypertension

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Jul 2010 Euthymics Bioscience acquires DOV Pharmaceutical
  • 24 Mar 2009 Phase-III clinical trials in Angina pectoris in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top